Investment Q&A

Q: This morning, Opsens received a takeover offer from Haemonetics. Do you think there's any potential for other bidders to offer more than the current $2.90 cash offer?

Many thanks.

Q: The market seems to like the news but I would appreciate your views on their just released Q1 results. I realize that they still came in at a loss but that was solely attributable to an increase in operating costs (specifically R&D and a ramp up of its US sales force in advance of the release of SavvyWire). I remain surprised that we're still trading below their recent financing level. Thanks as always.

Q: 1] Opsens Inc XTSE: OPS $2.23 CAD▲ +0.05 (+2.29%) today

2] OpSens Inc.

Short Description: Treasury Offering of Common Shares

Price: $1.90 CND per share.

Settlement: December 22, 2022.

Are 1 & 2 the same?

What does it do exactly? How do I buy it at $1.90? Is it worth buying?

Thank you.

Q: What are your thoughts on Pink & Opsens at this time? Thanks

Q: Your comments please on the FDA clearance. Any idea what the size of the market is for their product? What is their cash situation like... does it seem likely that they may need a financing round in the short term? Thanks.

Q: Looking at investing in these 3 stocks. What do you think the short term outlook for these 3 are and if you had to choose one to invest in which would it be. Thanks. Steve

Q: As can be seen from today's NR, we may now be off to the races with OPS. Would appreciate your views.

QUEBEC CITY, April 26, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received Health Canada approval for the SavvyWire™, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR.

Q: Your thoughts on the quarterly results.
Thanks John

Q: Is Opsens a buy with good growth potential?

Q: Would appreciate your analysis of yesterday's Q4 and FY 2021 results. At first glance, the 11 % decline in SP seems to be an overreaction.

Thanks as always

Q: Hi 5i,
I have the following in a non-registered (and high risk tolerance) account:
LSPD (+55%)
GAN (-21%)
XBC (-65%)
QUIS (+21%)
AMY (+28%)
PLTR (-15%)
NANO (-28%)
OPS (+37%)
PLUG (-62%)

1. Is there any names on this list that you would consider selling at a loss and re-deploying elsewhere?

2. I'd like to buy LSPD in my separate registered account considering the sharp drop over the past couple weeks. Is there any limitations on owning the same stock in both registered and non-registered accounts? I am comfortable in my overall position so that would not be a concern.

Please deduct credits as you see fit.

(There is a chance I've submitted this question twice; if so, please answer this one. My browser crashed during my first submission and I'm not sure if the first one went through.)

Thanks for your insight,
Kyle

Q: Hi Guys
What do you think of this company, I don't really understand their technology, but the way I read it, it has been "derisked", because they are going into human trails, is this a case of it been binary, if it works it will have good upside, if it fails, its goodbye Charlie

Thanks

Q: I'm looking for small caps to replace the nice win with PHO and want to increase my exposure to Healthcare. Do you have any thoughts on these names for exposure in this space? Thank you.

Q: Could you please provide your latest thoughts on this company. Back in February you appear to be favourable Has your opinion changed after they reported in April. The stock has been acting very well from a technical perspective.
I am thinking of taking an initial position in my TFSA.
Thanks for the years of many successful investment ideas.

Q: I would like your analysis and opinion on both companies and what your thoughts are on them as a more speculative buy. How are they situated financially and is their product something that could be in demand? I believe NEO does have a dividend.
Thank you John

Q: Can I have your analysis of this med tech - looks like they are now profitable
and growing. Any insight on TAM and the outlook for growth appreciated.

Q: There seems to have been an increase in interest in Opsens judging by the recent rise in stock price and volume of trades. Other than the conference call on Thursday, I see no other news. Any idea what is happening?

Q: What’s your latest opinion on OPS?
Long term buy, hold or sell.
Thank you!
Nick

Q: Revenue seems to be progressing reasonably well for Opsens over the past few years but they still seem to run at a loss. I notice that the number of shares has also increased in the past few years. Two years ago, you reported that the insider ownership was 14%. Is that still the case?

Q: Is it a long or short term buy right now at these levels after today’s earnings or do we just leave it alone?